Eli Lilly climbs on strong Q3 earnings results
Eli Lilly reported strong Q3 earnings, raising its full-year forecast. Key drugs Mounjaro and Zepbound generated $10.7B and $5.35B in sales, respectively, contributing to total revenue of $24.4B. The company also announced positive study results for Retatrutide, aiming for approval in 2027. Shares are up 20% year-to-date, contrasting with Novo Nordisk's 25% decline.
How this was made
The 30-second read
Why it matters
LLY’s forecast increase tied to obesity/diabetes sales supports bullish repricing. CAT’s shares drop despite beating EPS and revenue, suggesting the market’s expectations were higher than the reported results and/or forward demand signals.
Market read
Traders get same-day, company-specific catalysts: LLY guidance raise and CAT post-earnings disappointment despite a beat.
What to watch
For LLY, the article flags retatrutide’s sleep apnea study and potential approval timeline, but near-term valuation may hinge more on Zepbound growth vs Novo. For CAT, the key debate is whether order backlog and tariff-cost commentary offset the market’s expectation gap.
Background
The piece is a post-earnings discussion covering Eli Lilly’s Q3 performance and guidance raise, plus Caterpillar’s Q3 beat followed by a sharp selloff.
Ticker impact
Eli Lilly raised its full-year forecast after Q3 results, citing strong Mounjaro and Zepbound sales and higher revenue mix from obesity/diabetes drugs.
Likely upward bias as the market reprices full-year growth expectations on the guidance raise.
The article explicitly links the forecast increase to Q3 performance and provides segment sales figures, which are direct inputs to forward estimates.
Caterpillar reported Q3 results that beat EPS and revenue, but the stock fell sharply because the beat was not large enough versus expectations.
Likely continued pressure or choppy trading as investors focus on the magnitude of the beat and forward demand commentary.
The article attributes the selloff to the beat being insufficient and highlights guidance-like commentary (construction sales similar to prior year, modest volume down) plus backlog details.
Market effects
Reinforces obesity-drug demand momentum for GLP-1 peers while highlighting that industrial cyclicals can sell off even on beats when expectations are high.
US large-cap pharma and industrials sentiment spillover into broader growth and defensives.
Competitive read-through for global GLP-1 market share and ongoing AI-infrastructure capex demand signals for industrial equipment.
Counterpoint
LLY’s guidance raise may already be partially priced given the obesity narrative, while CAT’s backlog strength could mean the selloff is overdone if end-market durability holds.
Key entities
- companyEli Lilly
Raised full-year forecast after Q3 results; cited Mounjaro and Zepbound sales and a retatrutide sleep apnea study plan.
- companyCaterpillar
Reported Q3 EPS and revenue beats with strong backlog, but shares fell because the beat was not large enough versus expectations.
- companyNovo Nordisk
Mentioned as the main competitor; its shares are described as moving opposite to Lilly, with next-week reporting referenced.
